Autolus Historical Balance Sheet

AUTL Stock

USD 2.98 0.04 1.36%

Trend analysis of Autolus Therapeutics balance sheet accounts such as Other Current Liab of 36.3 M, Total Current Liabilities of 23.4 M or Total Stockholder Equity of 196.4 M provides information on Autolus Therapeutics' total assets, liabilities, and equity, which is the actual value of Autolus Therapeutics to its prevalent stockholders. By breaking down trends over time using Autolus Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Autolus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Autolus Therapeutics is a good buy for the upcoming year.

Autolus Therapeutics Inventory

(22.32 Million)

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

About Autolus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Autolus Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Autolus Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Autolus Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Autolus currently owns. An asset can also be divided into two categories, current and non-current.

Autolus Therapeutics Balance Sheet Chart

At this time, Autolus Therapeutics' Short and Long Term Debt Total is quite stable compared to the past year. Other Liabilities is expected to rise to about 152.2 M this year, although the value of Total Current Liabilities will most likely fall to about 23.4 M.

Total Assets Other Current Liab Total Current Liabilities Total Stockholder Equity Intangible Assets

Add Fundamental

Total Assets

Total assets refers to the total amount of Autolus Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Autolus Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Autolus Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Autolus Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Intangible Assets

Non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value.

Most accounts from Autolus Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Autolus Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.At this time, Autolus Therapeutics' Short and Long Term Debt Total is quite stable compared to the past year. Other Liabilities is expected to rise to about 152.2 M this year, although the value of Total Current Liabilities will most likely fall to about 23.4 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	23.7M	35.8M	34.5M	36.3M
Total Assets	405.6M	490.3M	375.4M	275.2M

Other Current Liab Total Assets

Autolus Therapeutics balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Net Receivables	Other Current Assets	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Total Assets		0.76	0.91	0.8	0.86	-0.65	-0.22	0.95	0.09	0.77	0.65	0.98	-0.71	0.7	0.77	0.58	0.68	0.65	-0.71	0.73	0.21	0.83	0.57	0.6	0.78	0.85
Other Current Liab	0.76		0.8	0.42	0.61	-0.77	-0.28	0.68	-0.22	0.88	0.86	0.7	-0.64	0.89	0.64	0.72	0.83	0.77	-0.49	0.71	0.15	0.63	0.82	0.84	0.54	0.76
Total Current Liabilities	0.91	0.8		0.52	0.69	-0.8	-0.43	0.77	0.14	0.82	0.79	0.82	-0.83	0.8	0.9	0.78	0.82	0.82	-0.52	0.91	0.23	0.71	0.7	0.74	0.8	0.94
Total Stockholder Equity	0.8	0.42	0.52		0.78	-0.18	0.16	0.86	0.25	0.38	0.19	0.86	-0.37	0.26	0.46	0.19	0.22	0.26	-0.66	0.31	0.17	0.68	0.12	0.13	0.55	0.41
Net Tangible Assets	0.86	0.61	0.69	0.78		-0.32	0.22	0.88	0.08	0.47	0.43	0.87	-0.36	0.48	0.53	0.34	0.42	0.4	-0.59	0.51	-0.13	0.66	0.42	0.39	0.71	0.55
Retained Earnings	-0.65	-0.77	-0.8	-0.18	-0.32		0.79	-0.48	0.1	-0.92	-0.94	-0.54	0.91	-0.92	-0.74	-0.88	-0.95	-0.92	0.33	-0.81	-0.36	-0.53	-0.89	-0.93	-0.5	-0.91
Accounts Payable	-0.22	-0.28	-0.43	0.16	0.22	0.79		-0.03	0.0	-0.59	-0.56	-0.11	0.78	-0.52	-0.49	-0.62	-0.62	-0.63	0.04	-0.54	-0.58	-0.19	-0.49	-0.57	-0.16	-0.66
Cash	0.95	0.68	0.77	0.86	0.88	-0.48	-0.03		-0.07	0.68	0.52	0.99	-0.51	0.6	0.55	0.34	0.54	0.43	-0.81	0.49	0.11	0.86	0.45	0.48	0.66	0.7
Net Receivables	0.09	-0.22	0.14	0.25	0.08	0.1	0.0	-0.07		-0.32	-0.2	0.0	-0.23	-0.24	0.45	0.26	-0.13	0.2	0.32	0.32	0.17	-0.21	-0.25	-0.25	0.3	-0.01
Other Current Assets	0.77	0.88	0.82	0.38	0.47	-0.92	-0.59	0.68	-0.32		0.89	0.71	-0.8	0.91	0.66	0.72	0.89	0.79	-0.58	0.71	0.32	0.72	0.83	0.88	0.52	0.91
Total Liab	0.65	0.86	0.79	0.19	0.43	-0.94	-0.56	0.52	-0.2	0.89		0.56	-0.78	0.99	0.64	0.85	0.99	0.89	-0.37	0.74	0.13	0.54	0.98	1.0	0.48	0.82
Total Current Assets	0.98	0.7	0.82	0.86	0.87	-0.54	-0.11	0.99	0.0	0.71	0.56		-0.59	0.63	0.64	0.43	0.59	0.51	-0.79	0.58	0.16	0.86	0.48	0.52	0.7	0.76
Intangible Assets	-0.71	-0.64	-0.83	-0.37	-0.36	0.91	0.78	-0.51	-0.23	-0.8	-0.78	-0.59		-0.76	-0.87	-0.88	-0.83	-0.91	0.37	-0.88	-0.43	-0.58	-0.71	-0.75	-0.67	-0.91
Common Stock	0.7	0.89	0.8	0.26	0.48	-0.92	-0.52	0.6	-0.24	0.91	0.99	0.63	-0.76		0.63	0.81	0.98	0.85	-0.45	0.72	0.13	0.6	0.96	0.99	0.49	0.83
Property Plant Equipment	0.77	0.64	0.9	0.46	0.53	-0.74	-0.49	0.55	0.45	0.66	0.64	0.64	-0.87	0.63		0.85	0.67	0.87	-0.25	0.97	0.4	0.48	0.55	0.59	0.77	0.85
Short Long Term Debt Total	0.58	0.72	0.78	0.19	0.34	-0.88	-0.62	0.34	0.26	0.72	0.85	0.43	-0.88	0.81	0.85		0.86	0.99	-0.09	0.9	0.31	0.32	0.82	0.83	0.57	0.77
Other Liab	0.68	0.83	0.82	0.22	0.42	-0.95	-0.62	0.54	-0.13	0.89	0.99	0.59	-0.83	0.98	0.67	0.86		0.89	-0.4	0.76	0.16	0.57	0.95	0.98	0.51	0.85
Property Plant And Equipment Net	0.65	0.77	0.82	0.26	0.4	-0.92	-0.63	0.43	0.2	0.79	0.89	0.51	-0.91	0.85	0.87	0.99	0.89		-0.2	0.92	0.3	0.43	0.85	0.87	0.62	0.83
Net Debt	-0.71	-0.49	-0.52	-0.66	-0.59	0.33	0.04	-0.81	0.32	-0.58	-0.37	-0.79	0.37	-0.45	-0.25	-0.09	-0.4	-0.2		-0.26	0.08	-0.97	-0.34	-0.34	-0.6	-0.53
Non Current Assets Total	0.73	0.71	0.91	0.31	0.51	-0.81	-0.54	0.49	0.32	0.71	0.74	0.58	-0.88	0.72	0.97	0.9	0.76	0.92	-0.26		0.28	0.49	0.69	0.71	0.8	0.88
Non Currrent Assets Other	0.21	0.15	0.23	0.17	-0.13	-0.36	-0.58	0.11	0.17	0.32	0.13	0.16	-0.43	0.13	0.4	0.31	0.16	0.3	0.08	0.28		0.01	-0.01	0.11	-0.07	0.36
Cash And Short Term Investments	0.83	0.63	0.71	0.68	0.66	-0.53	-0.19	0.86	-0.21	0.72	0.54	0.86	-0.58	0.6	0.48	0.32	0.57	0.43	-0.97	0.49	0.01		0.49	0.51	0.74	0.71
Common Stock Shares Outstanding	0.57	0.82	0.7	0.12	0.42	-0.89	-0.49	0.45	-0.25	0.83	0.98	0.48	-0.71	0.96	0.55	0.82	0.95	0.85	-0.34	0.69	-0.01	0.49		0.98	0.47	0.74
Non Current Liabilities Total	0.6	0.84	0.74	0.13	0.39	-0.93	-0.57	0.48	-0.25	0.88	1.0	0.52	-0.75	0.99	0.59	0.83	0.98	0.87	-0.34	0.71	0.11	0.51	0.98		0.44	0.79
Capital Surpluse	0.78	0.54	0.8	0.55	0.71	-0.5	-0.16	0.66	0.3	0.52	0.48	0.7	-0.67	0.49	0.77	0.57	0.51	0.62	-0.6	0.8	-0.07	0.74	0.47	0.44		0.72
Other Stockholder Equity	0.85	0.76	0.94	0.41	0.55	-0.91	-0.66	0.7	-0.01	0.91	0.82	0.76	-0.91	0.83	0.85	0.77	0.85	0.83	-0.53	0.88	0.36	0.71	0.74	0.79	0.72

Click cells to compare fundamentals

Autolus Therapeutics Account Relationship Matchups

Autolus Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	303.5M	294.2M	405.6M	490.3M	375.4M	275.2M
Other Current Liab	716K	24.2M	23.7M	35.8M	34.5M	36.3M
Total Current Liabilities	25.0M	33.6M	28.6M	46.4M	44.7M	23.4M
Total Stockholder Equity	254.8M	210.0M	313.3M	298.7M	111.5M	196.4M
Net Tangible Assets	254.6M	209.9M	313.3M	298.7M	343.5M	213.2M
Retained Earnings	(237.2M)	(379.2M)	(521.3M)	(670.2M)	(878.6M)	(834.6M)
Accounts Payable	1.1M	2.3M	431K	531K	103K	97.9K
Cash	210.6M	153.3M	310.3M	382.4M	239.6M	203.1M
Net Receivables	30.5M	29.7M	68K	153K	1.0M	994.6K
Other Current Assets	279K	14M	36.5M	43.2M	34.7M	36.4M
Total Liab	48.7M	84.2M	92.2M	191.6M	263.9M	277.1M
Total Current Assets	249.3M	197.0M	347.0M	425.8M	275.3M	228.1M
Common Stock	2K	3K	4K	8K	9.2K	9.7K
Property Plant Equipment	51.6M	89.7M	52.3M	58.4M	67.2M	36.1M
Short Long Term Debt Total	26.2M	54.2M	21.0M	24.3M	53.0M	55.6M
Other Liab	1.0M	492K	47.1M	126.0M	144.9M	152.2M
Property Plant And Equipment Net	51.6M	89.7M	52.3M	58.4M	95.7M	100.4M
Net Debt	(184.4M)	(99.1M)	(289.3M)	(358.2M)	(186.6M)	(195.9M)
Non Current Assets Total	54.3M	97.3M	58.6M	64.5M	100.1M	51.5M
Non Currrent Assets Other	2.0M	5.7M	4.4M	4.0M	1.4M	2.6M
Cash And Short Term Investments	210.6M	153.3M	310.3M	382.4M	239.6M	224.9M
Common Stock Shares Outstanding	43.1M	51.6M	72.1M	95.0M	173.9M	182.6M
Liabilities And Stockholders Equity	303.5M	294.2M	405.6M	490.3M	375.4M	304.0M
Non Current Liabilities Total	23.7M	50.6M	63.7M	145.2M	219.2M	230.1M
Other Stockholder Equity	500.7M	595.1M	843.2M	1.0B	1.0B	545.0M
Property Plant And Equipment Gross	51.6M	89.7M	75.0M	86.0M	124.4M	130.6M
Accumulated Other Comprehensive Income	(8.7M)	(5.9M)	(8.6M)	(38.9M)	(29.0M)	(30.4M)
Inventory	7.8M	(29.7M)	10.1M	14.2M	(23.5M)	(22.3M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:

How To Invest In Autolus

Details

Is Autolus Stock a good investment?

Details

What is Autolus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.22)

Revenue Per Share

0.043

Quarterly Revenue Growth

6.81

Return On Assets

(0.22)

Return On Equity

(0.82)

The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Autolus Historical Balance Sheet

Autolus Therapeutics Inventory

(22.32 Million)

About Autolus Balance Sheet Analysis

Autolus Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Intangible Assets

Autolus Therapeutics balance sheet Correlations

Autolus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Autolus Therapeutics balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 1.0	Total Liab
Total Current Assets	+ 0.99	Cash
Common Stock	+ 0.99	Total Liab
Other Liab	+ 0.99	Total Liab
Non Current Liabilities Total	+ 0.99	Common Stock
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total

Cash And Short Term Investments	- 0.97	Net Debt
Other Liab	- 0.95	Retained Earnings
Total Liab	- 0.94	Retained Earnings
Non Current Liabilities Total	- 0.93	Retained Earnings
Property Plant And Equipment Net	- 0.92	Retained Earnings
Common Stock	- 0.92	Retained Earnings